Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The ESC HF III Registry found substantial mortality and rehospitalization across heart failure phenotypes. Risk was highest after acute hospitalization and generally worse with reduced ejection fraction, but HFmrEF and HFpEF also carried si
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
Withdrawal of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists in patients with heart failure and improved ejection fraction significantly increases 1-year cardiovascular mortality and hospitalization risks; beta-bloc
Remote monitoring of systolic, diastolic, and mean pulmonary artery pressures predicts 2-year all-cause mortality in chronic heart failure across ejection fraction categories, informing personalized management strategies.